Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987 Titre : Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2014 Article en page(s) : p.981-987 Langues : Anglais (eng) Mots-clés : Acamprosate  Autism spectrum disorder  Glutamate  Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ?25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228 [article] Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2014 . - p.981-987. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987 Mots-clés : Acamprosate  Autism spectrum disorder  Glutamate  Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ?25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228

---

1 (1 - 1 / 1)